Introduction
============

Hyperuricemia has been reported to be an independent risk factor for hypertension,[@b1-cpaa-6-079],[@b2-cpaa-6-079] cardiovascular diseases,[@b3-cpaa-6-079] and kidney diseases.[@b4-cpaa-6-079] Approximately 25% of patients with hypertension have hyperuricemia,[@b1-cpaa-6-079] while approximately 30% of patients with hyperuricemia or gout have hypertension.[@b2-cpaa-6-079] In diabetic patients, hypertension and decreased renal function with hyperuricemia are major problems.[@b5-cpaa-6-079] Therefore, the effects of antihypertensive drugs on serum uric acid level (SUA), especially angiotensin II receptor blockers (ARBs), have been closely scrutinized in recent years.

We have examined the influence on SUA by ARBs and shown that one of the ARBs, irbesartan, inhibits uric acid (UA) transport via the renal UA transporters, urate transporter 1 (URAT1) and glucose transporter 9 (GLUT9).[@b6-cpaa-6-079] URAT1 is involved in lumen-to-cytosol reabsorption of UA at the apical membrane of proximal tubules,[@b7-cpaa-6-079] whereas GLUT9 functions as a UA efflux transporter from tubular cells at the basolateral membrane.[@b8-cpaa-6-079] Mutations of URAT1 or GLUT9 are associated with renal hypouricemia,[@b9-cpaa-6-079]--[@b11-cpaa-6-079] indicating that these two transporters play a dominant role in renal UA reabsorption and regulation of SUA. We previously reported that irbesartan (100--500 μM) inhibited the uptake of UA via both URAT1 and GLUT9 in vitro.[@b6-cpaa-6-079] Losartan has been shown to increase urinary UA excretion and to decrease SUA.[@b12-cpaa-6-079] Losartan is associated with a lower risk of incident gout among patients with hypertension.[@b13-cpaa-6-079] Since losartan is not effective for hypouricemic patients harboring URAT1 mutation, it has been demonstrated that the uricosuric action of losartan is via the inhibition of URAT1.[@b14-cpaa-6-079] The URAT1 inhibitory effects of irbesartan exceeded those of losartan in vitro, and the results suggest that irbesartan has the effect of decreasing SUA through increasing urinary UA excretion.[@b6-cpaa-6-079] Except for losartan and irbesartan, ARBs have been reported to increase the risk of gout[@b13-cpaa-6-079] and to increase the SUA.[@b15-cpaa-6-079] If irbesartan decreases SUA, its multiple effects would also make it useful for the treatment of hypertension combined with hyperuricemia.

A large study was performed in hypertensive patients with hyperuricemia to examine the effects of irbesartan on SUA for 2 months.[@b16-cpaa-6-079] Although the SUA decrease was observed in irbesartan-treated subjects (from 7.06 mg/dL baseline to 6.85 mg/dL), it was not significant and was less than in those treated with losartan (from 7.09 mg/dL to 6.03 mg/dL).[@b16-cpaa-6-079] In contrast, irbesartan was reported to decrease SUA significantly in hypertensive patients with advanced chronic renal disease.[@b17-cpaa-6-079] Since inconsistent results have been reported regarding its effects on SUA, it is necessary to determine whether irbesartan has an SUA decreasing effect. In the present study, we investigated the effects of irbesartan on SUA in hypertensive diabetic patients treated with 50--150 mg irbesartan.

Subjects and methods
====================

Subjects
--------

The study was approved by the Ethics Committee of Tokyo University of Pharmacy and Life Sciences and carried out in accordance with recommendations from the Declaration of Helsinki. This was a retrospective study performed at a diabetic clinic in Chigasaki (Japan). The subjects were 134 stable diabetic outpatients treated with irbesartan for 6--12 months in 2011--2012. We excluded 27 patients treated with drugs that influenced SUA such as allopurinol, diuretics, or fenofibrate. The remaining 107 patients were examined in this study. Out of these, 72 patients had been previously treated with other ARBs and the medicine was switched to irbesartan (designated the ARBs--IRB switch group). Other patients were started on irbesartan as the first ARB (designated the IRB group). Diabetic nephropathy was staged according to an analysis of the urinary albumin excretion (UAE) and eGFR as defined by the Japanese Society of Nephrology from the Japanese historical cohort study:[@b18-cpaa-6-079] stage I, UAE \<30 mg/g creatinine; stage II, 30≤ UAE \<300 mg/g creatinine; stage III, UAE ≥300 mg/g creatinine or continuous proteinuria (0.5 g/g creatinine ≤); stage IV, eGFR \<30 mL/min/1.73 m^2^. Seven patients had the complication of myocardial disease and four of them were treated with a calcium channel blocker in combination with irbesartan. Three other patients had stopped treatment with anticoagulant, calcium channel blocker or nitrate before irbesartan was started. The dose of irbesartan was 50--150 mg. The follow-up period was 12 months for 101 patients and 6 months for the other six patients. Systolic blood pressure (SBP) and diastolic blood pressure (DBP) were recorded before irbesartan treatment (pre), at the beginning of the study (0 month), and 1, 3, 6, and 12 months after irbesartan was started. Serum creatinine (SCr) and SUA were measured at the same time point as SBP and DBP. Estimated glomerular filtration rate (eGFR) was calculated from SCr, sex, and patients' age. The calculation formula defined by the Japanese Society of Nephrology is:
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Baseline values were calculated as the average of values between pre-treatment examinations and month zero.

Statistical analysis
--------------------

The data are presented as means ± SD. Student's *t*-test was adopted to compare continuous variables and a value of *P*\<0.05 was considered significant. Univariate logistic regression analysis was used to identify the factors associated with SUA changes. SUA decline after 6 or 12 months' irbesartan treatment was employed as the dependent variable. We introduced significant (*P*\<0.05) independent variables from the univariate analysis into multiple logistic regression analysis. The sex, history of alcohol intake, and diabetic disease duration were included in the multiple logistic regression analysis as independent variables. The receiver operating characteristic (ROC) curves were used to estimate the SUA cut-off point and this was determined to be where the sum of sensitivity and specificity was maximized. The Bonferroni multi-comparison test method[@b19-cpaa-6-079] was used when correcting for redundancy as required and *P*-values \<0.05 were again considered to be statistically significant. To compare the time-series data, we introduced a mixed-linear model adjusted for the cutoff of SUA baseline (\<5.9 mg/dL or ≥5.9 mg/dL) and the treatment before irbesartan (the IRB group or the ARBs--IRB switch group) as fixed effects. Analyses were performed with subjects as random effects. Data were analyzed using SPSS statistical software package for Windows (v21.0; SPSS Inc., Chicago, IL, USA).

Results and discussion
======================

Here, the SUA-depressing effect of irbesartan was investigated retrospectively in 107 hypertensive outpatients with diabetes. The clinical characteristics of the patients are shown in [Table 1](#t1-cpaa-6-079){ref-type="table"}. Patients in the ARBs--IRB switch group had significantly lower baselines of SBP and DBP than those of the IRB group because of their antihypertensive treatment. The ARB treatment is reported to decrease blood glucose level and total cholesterol.[@b20-cpaa-6-079],[@b21-cpaa-6-079] In agreement with those reports, the ARBs--IRB switch group showed significantly lower glucose baseline and low density lipoprotein-cholesterol baseline than the IRB group ([Table 1](#t1-cpaa-6-079){ref-type="table"}). There were no significant differences between baseline values of SCr and eGFR in the IRB and ARBs--IRB switch groups. The ARBs--IRB switch group had statistically significantly higher SUA baseline than the IRB group. The possibility of SUA increase by the pre-treatment of ARBs was examined in 53 cases from 72 patients of the ARBs--IRB switch group. The SUA at 6--12 months did not change significantly from the ARB-naïve baseline values. The number of patients who had elevated SUA from the start of ARB use was almost the same as that of patients with decreased SUA ([Table S1](#SD2-cpaa-6-079){ref-type="supplementary-material"}). From those results, the ARB pre-treatment was estimated not to be correlated with SUA increase. The baseline values of BP, SCr, eGFR, and SUA of the patients diagnosed with diabetic nephropathy are shown in [Table S2](#SD3-cpaa-6-079){ref-type="supplementary-material"}. The stages of diabetic nephropathy did not significantly influence these baseline values. No patients developed gout or showed renal stone formation during the study period.

The HbA~1c~ values at 6--12 months did not change significantly from the baseline values (data not shown) and it was suggested that diabetes progression did not occur in the patients over the monitoring period.

Results for the change in blood pressure (BP) are shown in [Figure 1A](#f1-cpaa-6-079){ref-type="fig"}. The BP baseline values were compared with BP levels at 1--12 months. In all patients, BP was well-controlled in the follow-up period ([Figure 1A](#f1-cpaa-6-079){ref-type="fig"}). SBP levels were decreased significantly at 1, 6, 12 months from baseline and DBP levels were decreased significantly at 1, 3, 6, and 12 months ([Figure 1A](#f1-cpaa-6-079){ref-type="fig"}). There was no significant difference in BP between the IRB group and the ARBs--IRB switch group during the study (data not shown).

The eGFR did not change significantly from the baseline since irbesartan treatment started ([Figure 1B](#f1-cpaa-6-079){ref-type="fig"}).

The SUA of the subjects at the end of the study period was compared with the baseline values and the number of the patients with SUA decline was more than half of the patients ([Table S3](#SD4-cpaa-6-079){ref-type="supplementary-material"}). Thus, we performed univariate logistic regression analysis to identify the factors that influenced SUA changes after 6--12 months ([Table S4](#SD5-cpaa-6-079){ref-type="supplementary-material"}). SUA decline after 6--12 months was introduced as the dependent variable and some clinical factors were examined with positive effects for SUA changes. The SUA baseline tended to be higher in men than women ([Table 1](#t1-cpaa-6-079){ref-type="table"}); however, sex was not found to be a significant relative factor for SUA changes ([Table S4](#SD5-cpaa-6-079){ref-type="supplementary-material"}). The dose of irbesartan, the BP or SCr baseline values, and existence of diabetic nephropathy (stage II and III) were not found to be correlated to SUA. Cardiovascular diseases such as myocardial disease, cerebrovascular disease, and arteriosclerosis showed no significant effect on the SUA changes. The univariate logistic regression analysis revealed that ARBs--IRB switch, a history of alcohol intake, and higher SUA baseline caused significant SUA decline. Subsequently, we introduced the three significant variables from the univariate analysis into the multiple logistic regression analysis ([Table S4](#SD5-cpaa-6-079){ref-type="supplementary-material"}). The history of alcohol intake was not a significant variable in the multiple analyses. This may be due to the common restriction of alcohol intake under diabetes treatment. The ARBs--IRB switch and SUA baseline were determined to be significant relative factors in the final model. The ARBs--IRB switch group had significantly higher SUA baseline than the IRB group ([Table 1](#t1-cpaa-6-079){ref-type="table"}), and this could be the reason why the ARBs--IRB switch was a positive factor for SUA decline. The result of the multiple logistic regression analysis suggested that the higher SUA baseline led to SUA decline after irbesartan treatment.

We performed an ROC analysis to determine the cutoff SUA baseline for evaluating dependence of its effect on SUA decreases ([Figure S1](#SD1-cpaa-6-079){ref-type="supplementary-material"}). The ROC analysis showed that patients with ≥5.9 mg/dL SUA at baseline had a positive benefit in terms of SUA decline.

Based on the results of the ROC analysis, the subjects were classified into those with an SUA baseline \<5.9 mg/dL and those ≥5.9 mg/dL. There was no significant difference in the SUA between the ARBs--IRB and IRB groups except at baseline (data not shown). The irbesartan efficacy on SUA decrease was validated with a mixed-linear model using the 5.9 mg/dL cutoff. The results are shown in [Figure 2](#f2-cpaa-6-079){ref-type="fig"}. The group with an SUA baseline \<5.9 mg/dL showed no significant SUA changes during the study period with the mixed-linear model. Subjects in the SUA baseline ≥5.9 mg/dL group had significantly higher SUA than the other group over the monitoring period (*P*\<0.001) and their SUA decreased gradually in a time-dependent manner, with a significant decrease observed at 12 months (from the SUA baseline value 6.6±0.16 mg/dL to 6.2±0.16 mg/dL, *P*=0.010 by the Bonferroni method).

Conclusion
==========

The present study revealed that irbesartan showed a significant effect on SUA decline on patients with higher SUA baseline and that the effect of irbesartan was seen markedly in patients with SUA ≥5.9 mg/dL. This result demonstrates that irbesartan treatment could achieve a decrease of SUA in hyperuricemic patients. This multiple effect of irbesartan enables efficient treatment for diabetic patients with hypertension and hyperuricemia.

Supplementary material
======================

###### 

ROC analysis of SUA baseline values.

**Notes:** Decrease of SUA over 12 months was set to a positive influence and specificity and sensitivity of SUA baseline value were plotted. The cutoff point of SUA when the sum of specificity and sensitivity is maximized was 5.9 mg/dL (specificity, 0.860; sensitivity, 0.414). Area under the curve: 0.6540 and 95% CI: 0.5510--0.7569.

**Abbreviations:** CI, confidence interval; ROC, receiver operating characteristic; SUA, serum uric acid.

###### 

SUA changes of the ARBs--IRB switch group by the pre-treatment of ARBs

                                                  Number       
  ----------------------------------------------- -------- --- ----
  SUA at 6--12 months of the ARBs pre-treatment                
   Candesartan                                    15       0   12
   Telmisartan                                    9        2   10
   Valsartan                                      2        0   1
   Olmesartan                                     1        0   1
   Sum                                            27       2   24

**Note:** Baseline means the average of values between ARBs-naïve examinations and the onset of ARBs.

**Abbreviations:** ARB, angiotensin II receptor blockers; IRB, irbesartan; SUA, serum uric acid.

###### 

The baseline values of the subjects classified with the stages of diabetic nephropathy

                         Number   SBP (mmHg)   DBP (mmHg)   SCr (mg/dL)   eGFR (mL/min/1.73m^2^)   SUA (mg/dL)
  ---------------------- -------- ------------ ------------ ------------- ------------------------ -------------
  Diabetic nephropathy                                                                             
   Stage I               11       136±3.6      81±4.0       0.73±0.13     79±17                    5.7±0.92
   Stage II              50       136±4.7      79±5.3       0.79±0.19     71±18                    5.2±1.1
   Stage III             19       135±12       82±9.9       0.84±0.31     74±28                    5.8±1.1

**Note:** The values are represented as mean±standard deviation.

**Abbreviations:** DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; SBP, systolic blood pressure; SCr, serum creatinine; SUA, serum uric acid.

###### 

SUA changes from baseline after 6--12 months of irbesartan treatment

                                       Number of patients
  ------------------------------------ --------------------
  SUA at the end of the study period   
   ≥baseline                           50
   \<baseline                          57

**Abbreviation:** SUA, serum uric acid.

###### 

Logistic regression analysis of the factors associated with SUA decline

                              Univariate logistic regression analysis                    
  --------------------------- ------------------------------------------- -------------- -----------------------------------------------------
  Sex                                                                                    
   Male                       Reference                                                  
   Female                     0.620                                       0.283--1.356   0.231
  Age                         0.998                                       0.964--1.033   0.916
  Dose                                                                                   
   50 mg                      Reference                                                  
   100 mg                     0.783                                       0.257--2.391   0.668
   150 mg                     0.667                                       0.073--6.111   0.720
  ARBs pretreatment                                                                      
   IRB                        Reference                                                  
   ARBs--IRB switch           2.507                                       1.088--5.774   0.031[\*](#tfn10-cpaa-6-079){ref-type="table-fn"}
  Diabetic nephropathy                                                                   
   Stage II                   1.009                                       0.429--2.373   0.984
   Stage III                  0.560                                       0.174--1.801   0.331
  Myocardial disease          0.600                                       0.128--2.823   0.518
  Cerebrovascular disease     0.600                                       0.128--2.823   0.518
  Arteriosclerosis            ND                                          0.000--ND      0.999
  Diabetic disease duration   0.948                                       0.898--1.000   0.052
  History of alcohol intake   2.364                                       1.044--5.352   0.039[\*](#tfn10-cpaa-6-079){ref-type="table-fn"}
  SBP baseline                0.980                                       0.927--1.036   0.481
  DBP baseline                0.965                                       0.905--1.029   0.274
  HbA~1c~ baseline            0.965                                       0.676--1.379   0.847
  SCr baseline                1.908                                       0.482--7.553   0.357
  SUA baseline                1.714                                       1.168--2.515   0.006[\*\*](#tfn11-cpaa-6-079){ref-type="table-fn"}
                              **Multiple logistic regression analysis**                  
                                                                                         
                              **OR**                                      **95% CI**     ***P*-value**
  ARBs--IRB switch            2.710                                       1.028--7.144   0.044[\*](#tfn10-cpaa-6-079){ref-type="table-fn"}
  SUA baseline                1.609                                       1.050--2.467   0.029[\*](#tfn10-cpaa-6-079){ref-type="table-fn"}
  History of alcohol intake   1.576                                       0.612--4.057   0.346

**Notes:** SUA decline after 6--12 months was introduced as dependent variable and was coded 1.

*P*\<0.05;

*P*\<0.01.

**Abbreviations:** ARB, angiotensin II receptor blockers; CI, confidence interval; DBP, diastolic blood pressure; HbA~1c~, glycated hemoglobin; IRB, irbesartan; OR, odds ratio; ND, not determined; SBP, systolic blood pressure; SCr, serum creatinine; SUA, serum uric acid.
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![Changes in blood pressure (**A**) and eGFR (**B**) of a total of 107 patients from the baseline compared with 12 months' irbesartan treatment.\
**Notes:** \**P*\<0.05, \*\**P*\<0.01, \*\*\**P*\<0.001 versus the baseline.\
**Abbreviations:** DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; SBP, systolic blood pressure.](cpaa-6-079Fig1){#f1-cpaa-6-079}

![Mixed-linear model plots for SUA changes of patients classified according to SUA baseline value (\<5.9 mg/dL (**A**) or ≥5.9 mg/dL (**B**)). Estimated marginal means of SUA were plotted from SUA at 0--12 months in covariance with diabetic disease duration.\
**Note:** \**P*\<0.05 versus SUA baseline, calculated by the Bonferroni multi-comparison test method.\
**Abbreviation:** SUA, serum uric acid.](cpaa-6-079Fig2){#f2-cpaa-6-079}

###### 

Clinical characteristics of the patients

                                     Number/mean ± SD
  ---------------------------------- -----------------------------------------------------
  Age (years)                        68±11
  Men                                65
  Women                              42
  IRB                                35
  ARBs--IRB switch                   72
  Type I DM                          3
  Type II DM                         104
  Insulin treatment                  16
  Diabetic duration (years)          14±8
  BMI baseline (kg/m^2^)             
   IRB                               24.1±3.4
   ARBs--IRB switch                  24.4±3.7
   Total                             24.3±3.6
  SBP baseline (mmHg)                
   IRB                               137±8.5
   ARBs--IRB switch                  134±6.0[\*](#tfn1-cpaa-6-079){ref-type="table-fn"}
   Total                             135±7.0
  DBP baseline (mmHg)                
   IRB                               82±7.9
   ARBs--IRB switch                  79±5.2[\*\*](#tfn2-cpaa-6-079){ref-type="table-fn"}
   Total                             80±6.4
  Glucose baseline (mg/dL)           
   IRB                               165±72
   ARBs--IRB switch                  145±38[\*](#tfn1-cpaa-6-079){ref-type="table-fn"}
   Total                             152±52
  HbA~1c~ baseline (%)               
   IRB                               6.8±1.2
   ARBs--IRB switch                  6.6±0.98
   Total                             6.7±1.1
  HDL-C baseline (mg/dL)             
   IRB                               62±19
   ARBs--IRB switch                  56±17
   Total                             58±18
  LDL-C baseline (mg/dL)             
   IRB                               116±22
   ARBs--IRB switch                  107±23[\*](#tfn1-cpaa-6-079){ref-type="table-fn"}
   Total                             110±23
  TG baseline (mg/dL)                
   IRB                               142±67
   ARBs--IRB switch                  139±77
   Total                             140±74
  SCr baseline (mg/dL)               
   Male                              0.86±0.30
   Female                            0.65±0.14
   IRB                               0.75±0.31
   ARBs--IRB switch                  0.80±0.29
   Total                             0.79±0.27
  eGFR baseline (mL/min/1.73 m^2^)   
   Male                              74±22
   Female                            72±19
   IRB                               76±21
   ARBs--IRB switch                  72±21
   Total                             73±21
  SUA baseline (mg/dL)               
   Male                              5.7±1.1
   Female                            4.7±1.0
   IRB                               5.0±1.0
   ARBs--IRB switch                  5.4±1.1[\*](#tfn1-cpaa-6-079){ref-type="table-fn"}
   Total                             5.3±1.1
  Diabetic nephropathy               
   Stage I                           11
   Stage II                          50
   Stage III                         19
   Stage IV                          2
  Myocardial disease                 7
  Cerebrovascular disease            7
  Arteriosclerosis                   2

**Notes:**

*P*\<0.05,

*P*\<0.01 versus IRB group by Student's *t*-test.

**Abbreviations:** ARB, angiotensin II receptor blockers; BMI, body mass index; DBP, diastolic blood pressure; DM, diabetes mellitus; eGFR, estimated glomerular filtration rate; HbA~1c~, glycated hemoglobin; HDL-C, high-density lipoprotein cholesterol; IRB, irbesartan; LDL-C, low-density lipoprotein cholesterol; SBP, systolic blood pressure; SCr, serum creatinine; SD, standard deviation; SUA, serum uric acid; TG, triglyceride.
